Both p65BTK levels and its oncogenicity depend on the RAS/ERK/MAPK pathway and its inhibition primarily affects colon cancer cells with mutated TP53, suggesting that p65BTK could be a new therapeutic target in the colon cancer, in which both deregulation of the RAS/ERK/MAPK pathway and loss of p53 function have been shown (Grassilli et al., 2016). Here, TP53 is linked to malignant colon neoplasm.